BEGIN:VCALENDAR VERSION:2.0 PRODID:icalendar-ruby CALSCALE:GREGORIAN BEGIN:VEVENT DTSTAMP:20240328T134739Z UID:9317f5f7-31c1-41da-bdc6-14de12e708af DTSTART:20210924T080000 DTEND:20210925T080000 CLASS:PRIVATE DESCRIPTION:
 \;
\n\n \;
\n\nOn behal f of Pulsus Group\, we are honoured to invite you to join the 9th International Conference on Dementia and Dementia Care w hich will be held from September 24-25\, 2020 at London\, UK.
\n\nThe conference will be o rganized around the theme &ldquo\;Novel approaches in Dementia Tre atment and Care&rdquo\;.
\n\nDementia Care 2020 has been planned and implemented in accordance with the acc reditation requirements and policies of the Accreditation Committee.
\n \nWe will likely convey an extraordinary program which covers the whole range of research in Dementia and Dementia care and share the multifacete d encounters of different treatment methodology.
\n\nDementia Care 2 020 is an annual gabfest which glazes the entire range of research in Deme ntia and Dementia care and shares the various encounters of different trea tment methodology. It is the platform for all the innovators\, researchers \, organizations\, scholars to discuss and exhibit the recent advancements in the treatment\, care and management of Dementia and it also brings tog ether the researchers to dissertate novel drug discovery\, technical devel opment in care methods\, on-going clinical trials\, end of life issues and organizational development.
\n\nDementia still remains as one of th e challenges in health care Internationally. It is reported that\, across the globe about 35.6 million are living with Dementia and it is expected t o double by 2030 and triple by 2050.
\n\nThis conference will provid e scope for all the proficient people in the field of Neuro science and Ps ychiatry to accomplish their research relationships with each other and to discover global associates for future collaboration.
\n\n \;
\n\nWho should attend?
\n\n \;
\n\nWhy to attend?
\ n\nWith members from around the world focused on learning about Dementi a and its advances\; this is your best opportunity to reach the largest as semblage of participants from the Dementia community. Conduct presentation s\, distribute information\, meet with current and potential scientists\, make a splash with new discoveries in the Dementia treatment and diagnosis \, and receive name recognition at this 2-day event. World-renowned speake rs\, the most recent techniques\, developments\, and the newest updates in Dementia Care\, treatment\, diagnosis are hallmarks of this conference. p>\n
Session 01: Dementia
\n\nDement ia is a chronic Neurodegenerative disorder in which the complete deteriora tion of the intellectual functioning and behavior occurs.It results in pro gressive memory loss\, thus affecting the lifestyle of the people. Dementi a is not a single disease entity rather it is the group of symptoms. The c ommon symptoms includes personality changes\, inability to recognize\, emo tional problems\, a failing sense of direction.
\n\nIt is stat ed by Alzheimer'\;s society that around 50 million people are living wi th Dementia and it is also stated that for every three seconds\, a person is developing Dementia. Dementia is prevailing as one of the priority cond ition in the field of medicine. Dementia is main leading cause of death in England and Wales over heart diseases. Alzheimer&rsquo\;s disease< span> is 6th leading cause of death in the USA and it kills more than brea st and prostate cancer combined. To solve problems of globally various Dem entia conferences are arranged to find cure for Dementia society universal ly.
\n\nRelated Conference: International De mentia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer' \;s Association International Conference\, July 22-26\, 2020\, Chicago\, U SA | International Conference On Alzheimer&rsquo\;s Disease &\; Dementi a\, September17-19\, 2020\, Paris\, France | Research Conference 2020\, Ma rch 20 - 21\, London\, UK | National Dementia Conference\, May 15-16 2020\ , Melbourne\, Australia | Advances and Innovations in Dementia\, September 17-18\, 2020\, Singapore | International Conference on Alzheimer'\;s D isease &\; Dementia\, October 29-31 2020\, Valencia\, Spain |
\n\nRelated societies: Dementia Society of America | Alzheim er'\;s Association | Alzheimer'\;s Foundation of America | Alzheimer &rsquo\;s Society-United against dementia | ageUK | Alzheimer Society of C anada | Lewy Body Dementia Association |
\n\n \;
\n\nThe Reisberg scale is used to indicate the disease progression. If the per son has no memory loss and if he/she is mentally stable and healthy\, i.e\ , a normal person\, is said to be in no cognitive stage of the syndrome. T he stage 2 or very mild cognitive decline has no evident symptoms\, due to ageing the forgetfulness\, which is the common symptom emerges during thi s stage. During the third stage i.e\, mild cognitive decline stage people experience increased forgetfulness\, and face difficulty in finding words. Stage 4 or moderate cognitive decline includes severe symptoms like decre ase in concentration\, and the person faces difficulty such that he /she c ould not travel alone. In stage 5 or moderately severe cognitive decline o ccurs such that people have difficulties in completing tasks and people st art withdrawing from social activities. Next is the middle dementia where the people tend to forget the recent memory activities. The last stage is that they have no ability to talk or communicate. They completely require human help and care.
\n\nRelated Conference: World Congress &\; Expo on Dementia &\; Neuroscience\, November 12-14\, 20 20\, Toronto\, Canada | International Dementia Conference\, April 16-17\, 2020\, Dublin\, Ireland | International Dementia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer Europe Conference \, October 29-31 \, 2020\, Barcelona\, Spain | International Conference on Frontotemporal D ementias\, November 11-14\, 2020\, Sydney\, Australia | World Congress on Alzheimer'\;s Disease &\; Dementia\, May 30-31\, 2020 Osaka\, Japan | World Summit on Alzheimer&rsquo\;s Disease\, Neurophysiology and Cogniti ve Neuroscience\, August 31-September 01\, 2020\, Massachusetts\, USA |
\n\nRelated societies: The World Dementia Council | D ementia Australia | Motor Neurone Disease Association | Rare Dementia Supp ort | Association for Frontal Temporal Degeneration | National Stroke Asso ciation | Parkinsons Disease Foundation |
\n\n \;
\n\nAlzheimer&rs quo\;s disease is most common type of Dementia. Alzheimer&rsquo\;s is a ch ronic Neurodegenerative disorder. Patient of Alzheimer&rsquo\;s shows earl y symptoms of short term memory and later progresses to problems in langua ge\, disorientation. Causes of Alzheimer&rsquo\;s are not clear yet\, but 70% of risks are associated with genetics. There are no existing treatment s to reverse or stop Alzheimer&rsquo\;s. Most of patients with alzheimer&r squo\;s are above 65 years of age but 4-5% cases are of early onset Alzhei mer&rsquo\;s. It&rsquo\;s still one of the costly diseases. Separate Alzhe imer&rsquo\;s conferences has been arranged to make aware world for its co nsequences. In 2020\, hundreds of conferences has main topic as Alzheimer& rsquo\;s disease as it contributes to 60-70% cases of Dementia. Several co untries Governments are taking initiative in Alzheimer&rsquo\;s Congress s uch as UK\, USA\, Canada\, France having high ratio of deaths due to Alzhe imer&rsquo\;s patients and other Dementias.
\n\nRelated Conf erence: Neurological Disorders Summit\, July 23 - 25\, 2020\, Los Angeles\, USA | International Conference On Neurorehabilitation and Its A ssociated Disorders\, June 06 - 07\, Singapore | Global Insight Conference on Neurology &\; Brain Disorders\, October 18 - 20\, 2020\, Las Vegas\ , USA | Dementia 2020 conference\, April 16-18\, 2020 Tokyo\, Japan | Inte rnational Conference on Neurology and Brain disorders June 04-06\, 2020\, Rome\, Italy | Annual Conference on Dementia and Alzheimers Disease\, Dece mber 13-15\, 2020\, Abu Dhabi\, UAE | World Congress on Neurology and Neur odisorders\, July 16-17\, 2020\, Melbourne\, Australia |
\n\nRelated societies: American Parkinson Disease Association: Hope in Progress | Dementia Alliance International | Dementia Advocacy and Supp ort Network International | International Psychogeriatric Association | Wo rld Federation of Neurology | Child Neurology Society | American Neurologi cal Association |
\n\n \;
\n\nSession 04: Vascular Dementia
\n\nVascular Dementia is second most common type of Dementia after Alzheimer&rsquo\;s. Brain has one of the richest network s\, sudden changes in thinking causes problems in supply of oxygen and nut rients to brain\, causes series of minor attacks. Vascular Dementia can&rs quo\;t be tracked until it has series of attacks. Death of brain cells cau ses problems in memory\, thinking and reasoning. There are various types o f Vascular Dementia such as Stroke-related Dementia\, Post-stroke Dementia \, Single-infarct and Multi-infarct Dementia\, Sub cortical Dementia. High blood pressure\, High blood cholesterol level\, Diabetes are some risk fa ctors which majorly contribute to the severity of Vascular Dementia. Vascu lar Dementia is common type of Dementia after Alzheimer&rsquo\;s disease c ontributing to nearly 20% cases making it significant in discussions of De mentia conference.
\n\nRelated Conference: Internat ional Dementia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzhe imer'\;s Association International Conference\, July 22-26\, 2020\, Chi cago\, USA | International Conference On Alzheimer&rsquo\;s Disease &\; Dementia\, September17-19\, 2020\, Paris\, France | Research Conference 2 020\, March 20 - 21\, London\, UK | National Dementia Conference\, May 15- 16 2020\, Melbourne\, Australia | Advances and Innovations in Dementia\, S eptember 17-18\, 2020\, Singapore | International Conference on Alzheimer& #39\;s Disease &\; Dementia\, October 29-31 2020\, Valencia\, Spain | p>\n\n
Related societies: Dementia Society of America | Alzheimer'\;s Association | Alzheimer'\;s Foundation of America | A lzheimer&rsquo\;s Society-United against dementia | ageUK | Alzheimer Soci ety of Canada | Lewy Body Dementia Association |
\n\nSession 05: Dementia with Lewy Body
\n\nAlph a synuclein protein depositions in neurons cause Lewy body Dementia. Sympt oms of Lewy body Dementia are hallucinations\, rigidness in movement. In L ewy body Dementia\, disruption among brain cells occur\, after one year of observation and progression in symptoms with Parkinson&rsquo\;s disease t he diagnosis of Lewy body Dementia is possible. If cognitive problems occu r with a year of movement problems doctors declares it as Lewy body Dement ia and if not then it is declared as Parkinson&rsquo\;s disease. It is nor mal kind of Dementia after Alzheimer'\;s illness and having same cases as Vascular Dementia making it critical in interloculation of Dementia mee tings.
\n\nRelated Conference: World Congress &\ ; Expo on Dementia &\; Neuroscience\, November 12-14\, 2020\, Toronto\, Canada | International Dementia Conference\, April 16-17\, 2020\, Dublin\ , Ireland | International Dementia Conference\, June 07-08\, 2020\, Sydney \, Australia | Alzheimer Europe Conference \, October 29-31 \, 2020\, Barc elona\, Spain | International Conference on Frontotemporal Dementias\, Nov ember 11-14\, 2020\, Sydney\, Australia | World Congress on Alzheimer'\ ;s Disease &\; Dementia\, May 30-31\, 2020 Osaka\, Japan | World Summit on Alzheimer&rsquo\;s Disease\, Neurophysiology and Cognitive Neuroscienc e\, August 31-September 01\, 2020\, Massachusetts\, USA |
\n\n \;
\n\nSession 06 : Frontotemporal Dementia
\n\nFrontotemporal Dementia also known as Pick&rsquo\;s disease is broad term for group of disorders caused by progressive nerve cell loss in the frontal and temporal lobes of brain . Spindle neurons have 70% loss in Frontotemporal Dementia patients while other neurons remain unchanged. Temporal lobes have specific function such as right temporal lobe involved in recognition of faces and known objects . Left temporal lobe involved in meaning of names and words of objects. Fr ontotemporal Dementia includes changes in behavior\, personality and diffi culty in speech. It is significant cause of Dementia in younger people. MR I scans may show the frontal and temporal lobe atrophy.
\n\nRelated Conference: Neurological Disorders Summit\, July 23 - 25\ , 2020\, Los Angeles\, USA | International Conference On Neurorehabilitati on and Its Associated Disorders\, June 06 - 07\, Singapore | Global Insigh t Conference on Neurology &\; Brain Disorders\, October 18 - 20\, 2020\ , Las Vegas\, USA | Dementia 2020 conference\, April 16-18\, 2020 Tokyo\, Japan | International Conference on Neurology and Brain disorders June 04- 06\, 2020\, Rome\, Italy | Annual Conference on Dementia and Alzheimers Di sease\, December 13-15\, 2020\, Abu Dhabi\, UAE | World Congress on Neurol ogy and Neurodisorders\, July 16-17\, 2020\, Melbourne\, Australia |
\n \nRelated societies: American Parkinson Disease Associ ation: Hope in Progress | Dementia Alliance International | Dementia Advoc acy and Support Network International | International Psychogeriatric Asso ciation | World Federation of Neurology | Child Neurology Society | Americ an Neurological Association |
\n\n \;
\n\nSession 07: Posterior Cortical Atrophy
\n\nPosterior Cortical Atrop hy also called as Benson'\;s syndrome is a abberant variant of Alzheime r'\;s disease\, where the symptom is identified at the different part o f the brain. It is one of the common Neuro degenerative disorders where th e degeneration occurs in the cortex region of the brain. It is also due to the accumulation of amyloid protein in that region. The PCA affected pati ents show amyloid plaques and tangles in the neurofibrils. The challenge i s that this syndrome shows distinct Neuropsychological deficits still rema ining as the complicated forms of Dementia. PCA has been recognized for mo re than two decades\, and yet the condition is almost abandoned by researc hers. Hence it is the most suitable topic for discussion in the Dementia c onference.
\n\nRelated Conference: International De mentia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer' \;s Association International Conference\, July 22-26\, 2020\, Chicago\, U SA | International Conference On Alzheimer&rsquo\;s Disease &\; Dementi a\, September17-19\, 2020\, Paris\, France | Research Conference 2020\, Ma rch 20 - 21\, London\, UK | National Dementia Conference\, May 15-16 2020\ , Melbourne\, Australia | Advances and Innovations in Dementia\, September 17-18\, 2020\, Singapore | International Conference on Alzheimer'\;s D isease &\; Dementia\, October 29-31 2020\, Valencia\, Spain |
\n\nRelated societies: Dementia Society of America | Alzheim er'\;s Association | Alzheimer'\;s Foundation of America | Alzheimer &rsquo\;s Society-United against dementia | ageUK | Alzheimer Society of C anada | Lewy Body Dementia Association |
\n\n< strong>Session 08: Parkinson Disease Dementia
\n\nParkinson '\;s disease Dementia is a cognitive decline in thinking and reasoning that develops in the person diagnosed with Parkinson'\;s disease at lea st a year earlier. Parkinson'\;s Dementia are similar to those caused b y other health issues. For example\, mental health issues such as depressi on can mimic Dementia. The reason behind development of Dementia is not co mpletely understood in Parkinsons disease patient. Hence this conference w ill provide a platform to discuss the problem.
\n\nRelated C onference: World Congress &\; Expo on Dementia &\; Neurosci ence\, November 12-14\, 2020\, Toronto\, Canada | International Dementia C onference\, April 16-17\, 2020\, Dublin\, Ireland | International Dementia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer Europe Co nference \, October 29-31 \, 2020\, Barcelona\, Spain | International Conf erence on Frontotemporal Dementias\, November 11-14\, 2020\, Sydney\, Aust ralia | World Congress on Alzheimer'\;s Disease &\; Dementia\, May 3 0-31\, 2020 Osaka\, Japan | World Summit on Alzheimer&rsquo\;s Disease\, N europhysiology and Cognitive Neuroscience\, August 31-September 01\, 2020\ , Massachusetts\, USA |
\n\nRelated societies: The World Dementia Council | Dementia Australia | Motor Neurone Disease Associ ation | Rare Dementia Support | Association for Frontal Temporal Degenerat ion | National Stroke Association | Parkinsons Disease Foundation |
\n\ n \;
\n\nSession 09: Diseases associated with Dementi a
\n\nThe neurological conditions in which the Dementia occ urs include some disorders like Parkinson'\;s disease\, Normal Pressure Hydrocephalus\, Huntington'\;s disease\, and Creutzfeldt-Jakob disease (CJD). These diseases mimic Dementia or has Dementia as a major sign in t he disease. The diseases associated with Dementia have the disease associa tes that include depression\, brain tumors\, nutritional deficiencies\, he ad injuries\, hydrocephalus\, infections (AIDS\, meningitis\, syphilis)\, Drug reactions and Thyroid problems. The genetic factors are responsible f or the establishment of disorders like Parkinsons disease\, Down Syndrome\ , Creutzfeldt-Jakob disease\, Normal Pressure Hydrocephalus\, The other fa ctors for Dementia includes physical factors like head injuries and Trauma tic brain injuries.
\n\nRelated Conference: Neurolo gical Disorders Summit\, July 23 - 25\, 2020\, Los Angeles\, USA | Interna tional Conference On Neurorehabilitation and Its Associated Disorders\, Ju ne 06 - 07\, Singapore | Global Insight Conference on Neurology &\; Bra in Disorders\, October 18 - 20\, 2020\, Las Vegas\, USA | Dementia 2020 co nference\, April 16-18\, 2020 Tokyo\, Japan | International Conference on Neurology and Brain disorders June 04-06\, 2020\, Rome\, Italy | Annual Co nference on Dementia and Alzheimers Disease\, December 13-15\, 2020\, Abu Dhabi\, UAE | World Congress on Neurology and Neurodisorders\, July 16-17\ , 2020\, Melbourne\, Australia |
\n\nRelated societies: American Parkinson Disease Association: Hope in Progress | Dementia A lliance International | Dementia Advocacy and Support Network Internationa l | International Psychogeriatric Association | World Federation of Neurol ogy | Child Neurology Society | American Neurological Association |
\n\ n \;
\n\nSession 10: Neuroepigenetics
\n\ nNeuroepigenetics is the field in Neuro biology that replaces the conve ntional thoughts on heritable epigenetic mechanisms\, which involves in hi stone and chromatin modification which results in the variable expression of genes in the CNS . The numerous neuroepigenetic mechanisms have been in volved in several Neurological and Neurodegenerative diseases for the regu lation of various epigenetic mechanisms. All the mechanisms in Epigenetics will have a biochemical characteristics such that it helps in regulation process.The basic principle of Neuroepigenetics is that once DNA methylati on patterns are established upon the genome in terminally differentiated c ells\, those modifications are permanent and essentially immutable. Other epigenetic molecular mechanisms are also in play in neurons some are ATP-d ependent chromatin remodeling\, genomic imprinting \, SNF2 chromatin remod eling.
\n\nRelated Conference: International Dement ia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer'\;s Association International Conference\, July 22-26\, 2020\, Chicago\, USA | International Conference On Alzheimer&rsquo\;s Disease &\; Dementia\, September17-19\, 2020\, Paris\, France | Research Conference 2020\, March 20 - 21\, London\, UK | National Dementia Conference\, May 15-16 2020\, Me lbourne\, Australia | Advances and Innovations in Dementia\, September 17- 18\, 2020\, Singapore | International Conference on Alzheimer'\;s Disea se &\; Dementia\, October 29-31 2020\, Valencia\, Spain |
\n\nRel ated societies: Related societies: Dementia Society of Am erica | Alzheimer'\;s Association | Alzheimer'\;s Foundation of Amer ica | Alzheimer&rsquo\;s Society-United against dementia | ageUK | Alzheim er Society of Canada | Lewy Body Dementia Association |
\n\nSession 11: Causes and Risk Factors
\n\nCauses of Dementia depend on areas of brain affected due to Dementia. D ementia is progressive in nature\; Age is one of the most important risk f actor of Dementia\, 65years exceeding persons has more chances of having D ementia. Ageing and genetic inheritance from ancestors is beyond control b ut other risk factors such as Hypertension\, Hyperlipidaemia\, Hyperthoiro idism\, Alcohol use in large amounts\, smoking can be prevented or control led. Head injury\, Stroke or Brain tumor may cause Dementia. Few risk fact ors can be prevented with healthy lifestyle and proper diet. Causes and ri sk elements have contributed enormously in Dementia research and discovere d new measures in Dementia conferences.
\n\nRelated Conferen ce: World Congress &\; Expo on Dementia &\; Neuroscience\, November 12-14\, 2020\, Toronto\, Canada | International Dementia Conferen ce\, April 16-17\, 2020\, Dublin\, Ireland | International Dementia Confer ence\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer Europe Conferenc e \, October 29-31 \, 2020\, Barcelona\, Spain | International Conference on Frontotemporal Dementias\, November 11-14\, 2020\, Sydney\, Australia | World Congress on Alzheimer'\;s Disease &\; Dementia\, May 30-31\, 2020 Osaka\, Japan | World Summit on Alzheimer&rsquo\;s Disease\, Neurophy siology and Cognitive Neuroscience\, August 31-September 01\, 2020\, Massa chusetts\, USA |
\n\nRelated societies: The World D ementia Council | Dementia Australia | Motor Neurone Disease Association | Rare Dementia Support | Association for Frontal Temporal Degeneration | N ational Stroke Association | Parkinsons Disease Foundation |
\n\n&nb sp\;
\n\nSession 12: Bioinformatics Approach
\n\ nBioinformatics advent can be used to regulate and evaluate data from t he current high-throughput research technologies and render means for nove l discoveries in the field of Neurodegenerative diseases. It is reported t hat there is a very little published data on Epigenomics. It is said that the data are obtained from high through put technologies in screening of h uman brain. These data intend the upcoming researchers to know and design their experiments. The Data Mining plays an important role in the predicti on of the disorder\, where the actual data is compared with the real data and the results are interpreted. The Transcriptomics and Proteomics studie s has also been carried out providing necessary solutions for the problems .
\n\nRelated Conference: Neurological Disorders Su mmit\, July 23 - 25\, 2020\, Los Angeles\, USA | International Conference On Neurorehabilitation and Its Associated Disorders\, June 06 - 07\, Singa pore | Global Insight Conference on Neurology &\; Brain Disorders\, Oct ober 18 - 20\, 2020\, Las Vegas\, USA | Dementia 2020 conference\, April 1 6-18\, 2020 Tokyo\, Japan | International Conference on Neurology and Brai n disorders June 04-06\, 2020\, Rome\, Italy | Annual Conference on Dement ia and Alzheimers Disease\, December 13-15\, 2020\, Abu Dhabi\, UAE | Worl d Congress on Neurology and Neurodisorders\, July 16-17\, 2020\, Melbourne \, Australia |
\n\nRelated societies: American Park inson Disease Association: Hope in Progress | Dementia Alliance Internatio nal | Dementia Advocacy and Support Network International | International Psychogeriatric Association | World Federation of Neurology | Child Neurol ogy Society | American Neurological Association |
\n\n \;
\n\ nSession 13: Recent Advances in Dementia Diagnosis
\n\nThe assessment of Dementia in needed to rule out similar symptoms s howing to such diseases such as depression\, delirium which is curable. It is necessary to provide time to Dementia patients to plan future and make them literate about the possible effects in the future. There are various tests for diagnosing Dementia such as Mini Mental State Examination (MMSE )\, Mental Score Test\, Trail Making Test. MMSE test include series of exe rcises in which various problems are checked with memory\, speech\, abilit y to respond. Blood test is also done to check levels of vitamin B12 and T hyroid hormones\, which may be responsible. Brain scans such as MRI and CT scans used for checking brain tumor and Strokes in Vascular Dementia. Neu rology gatherings talked rigorously on Dementia Diagnosis and it is always misleading to different conditions like Parkinson&rsquo\;s'\; disease. Hence discovery and establishment of new methodologies and techniques for analysis is in the urge for the Dementia society for dependable diagnosis methods.
\n\nRelated Conference: International Dem entia Conference\, June 07-08\, 2020\, Sydney\, Australia | Alzheimer'\ ;s Association International Conference\, July 22-26\, 2020\, Chicago\, US A | International Conference On Alzheimer&rsquo\;s Disease &\; Dementia \, September17-19\, 2020\, Paris\, France | Research Conference 2020\, Mar ch 20 - 21\, London\, UK | National Dementia Conference\, May 15-16 2020\, Melbourne\, Australia | Advances and Innovations in Dementia\, September 17-18\, 2020\, Singapore | International Conference on Alzheimer'\;s Di sease &\; Dementia\, October 29-31 2020\, Valencia\, Spain |
\n\nRelated societies: Dementia Society of America | Alzheime r'\;s Association | Alzheimer'\;s Foundation of America | Alzheimer& rsquo\;s Society-United against dementia | ageUK | Alzheimer Society of Ca nada | Lewy Body Dementia Association |
\n\nSession 14: Treatment Modalities
Treatment modali ty is a method that is followed to treat a patient suffering from a diseas e condition. The treatment modalities have three main approaches \,which i nclude medical\, psychological and sociocultural approaches. The most impo rtant consideration is that\, in practice\, no single treatment is conside red sufficient for the treatment of Dementia. By now the combination thera py which involves the use of two or more drugs proves to be efficient. The other treatment methods which involve the stem cell therapy and gene ther apy has now created the spotlight in the Dementia Treatment. Hence the adv anced treatment methods can be discussed in the conference.
\n\nRelated societies: The World Dementia Council | Dementia Australia | Motor Neurone Dis ease Association | Rare Dementia Support | Association for Frontal Tempora l Degeneration | National Stroke Association | Parkinsons Disease Foundati on |
\n\n \;
\n\nSession 15: Therapeutic Targets strong>
\n\nTherapeutic targets are bio molecules maybe a nucleic ac id or a protein whose biological activity can be modified by a drug candid ate. In some cases of Dementia\, it is reported that proteins are the caus e for the disease. For example the accumulation of amyloid protein in the regions of Brain acts as a major factor for the disorder\, hence it can be a therapeutic target . Therapeutic targets play an important role in iden tifying the potential drug candidates . Hence the conference provides the discussion sessions to reveal the targets for drug design process.
\n\nRelated Conference: Neurological Disorders Summit\, Ju ly 23 - 25\, 2020\, Los Angeles\, USA | International Conference On Neuror ehabilitation and Its Associated Disorders\, June 06 - 07\, Singapore | Gl obal Insight Conference on Neurology &\; Brain Disorders\, October 18 - 20\, 2020\, Las Vegas\, USA | Dementia 2020 conference\, April 16-18\, 20 20 Tokyo\, Japan | International Conference on Neurology and Brain disorde rs June 04-06\, 2020\, Rome\, Italy | Annual Conference on Dementia and Al zheimers Disease\, December 13-15\, 2020\, Abu Dhabi\, UAE | World Congres s on Neurology and Neurodisorders\, July 16-17\, 2020\, Melbourne\, Austra lia |
\n\nRelated societies: American Parkinson Disease Association: Hope in Progress | Dementia Allian ce International | Dementia Advocacy and Support Network International | I nternational Psychogeriatric Association | World Federation of Neurology | Child Neurology Society | American Neurological Association |
\n\n& nbsp\;
\n\nSession 16: Clinical Trials and Drug Development< /strong>
\n\nRigorous clinical trials on Dementia drugs are continui ng in USA and UK under the guidance of Alzheimer'\;s society and it is reported that there is very less participation of people . The most of dru gs are in second and third phases.. Most of clinical trials are done in sp ecific areas are amyloid beta plaques\, the immune system\, tau tangles . New medications for Dementia being developed in 2020/2020\, 31% were named symptoms modifying. There are many developments are going on in Drug disc overy of Dementia as old treatments are unable to stop the progression of Dementia. Most associations share their exploration on new medications for Dementia in Dementia conferences to get higher esteem to their items. Thi s gets to be distinctly gainful to different geriatric doctors to redesign themselves with such medications and progressing possibilities by going t o Dementia conferences. Such Dementia meetings will help researchers to kn ow target areas for Drug development in Dementia and work towards it and a lso Dementia conferences exhibit clinical trial medications and offers pos itivity to discover new approaches in curing Dementia
\n\nRe lated Conference: International Dementia Conference\, June 07-08\ , 2020\, Sydney\, Australia | Alzheimer'\;s Association International C onference\, July 22-26\, 2020\, Chicago\, USA | International Conference O n Alzheimer&rsquo\;s Disease &\; Dementia\, September17-19\, 2020\, Par is\, France | Research Conference 2020\, March 20 - 21\, London\, UK | Nat ional Dementia Conference\, May 15-16 2020\, Melbourne\, Australia | Advan ces and Innovations in Dementia\, September 17-18\, 2020\, Singapore | Int ernational Conference on Alzheimer'\;s Disease &\; Dementia\, Octobe r 29-31 2020\, Valencia\, Spain |
\n\nRelated societies: Dementia Society of America | Alzheimer'\;s Association | Alzheim er'\;s Foundation of America | Alzheimer&rsquo\;s Society-United agains t dementia | ageUK | Alzheimer Society of Canada | Lewy Body Dementia Asso ciation |
\n\n \;
\n\nSession 17: Awareness and Ca re Practices
\n\nDementia is predominant disorder that affe cts more number of people around the world. Diagnosis of the patient with Dementia frightens the person affected by the syndrome\, their family memb ers and caretakers. Better understanding about public awareness of Dementi a aids more effective health and social policies. Dementia patients need a ssistance and full time care as much as drugs. Some common care practices in Dementia are assistance in food and fluid consumption\, pain management \, social engagement ensuring safety and security of Dementia patients. Ma in aim of care practices is to ensure cut in hospitalization and psychotro pic drugs. Understanding patient&rsquo\;s mood changes\, particular behavi or\, speech problems and help in rectifying them. Dementia patients need e nd of life care so qualified nursing staff is needed. Few care practices w hich are used are indoor and outdoor activities\, visual and audio stimula tion\, Art therapy. Care practices in Dementia have been critical to engag e in international Dementia meetings. In need to evolve in Dementia care w orld gathering and genuine talks on Dementia care is required. The Dementi a conference discusses public awareness as well as care practices to achie ve higher rate of early diagnosis and to decrease the distress among the p atient\, family and caregivers.
\n\nRelated Conference: World Congress &\; Expo on Dementia &\; Neuroscience\, November 12-14\, 2020\, Toronto\, Canada | International Dementia Conference\, Apr il 16-17\, 2020\, Dublin\, Ireland | International Dementia Conference\, J une 07-08\, 2020\, Sydney\, Australia | Alzheimer Europe Conference \, Oct ober 29-31 \, 2020\, Barcelona\, Spain | International Conference on Front otemporal Dementias\, November 11-14\, 2020\, Sydney\, Australia | World C ongress on Alzheimer'\;s Disease &\; Dementia\, May 30-31\, 2020 Osa ka\, Japan | World Summit on Alzheimer&rsquo\;s Disease\, Neurophysiology and Cognitive Neuroscience\, August 31-September 01\, 2020\, Massachusetts \, USA |
\n\nRelated societies: The World Dementia Council | Dementia Australia | Motor Neurone Disease Association | Rare De mentia Support | Association for Frontal Temporal Degeneration | National Stroke Association | Parkinsons Disease Foundation |
\n\n \;
\n\nSession 18: Case reports
\n\nCase reports in Dementia supports the comprehensive report of causes\, symptoms\, treatme nt and possible outcome. Each case report distinguishes in conditions such as age\, family background\, treatment given and effects of it. This all helps to design\, categorize the future aspects of disease. Case report wi ll be highly helpful for the researchers to develop new methods for physic ians to develop quick diagnosis methods in Dementia patients. Case reports in Dementia gives some thought regarding diagnosis\, treatment and level of cure perhaps conceivable prevention to be taken moreover. Be that as it may\, most recognized case reports is to be talked in the Dementia confer ence which would be extremely useful to researchers to carry on with their work.
\n\nRelated Conference: Neurological Disorde rs Summit\, July 23 - 25\, 2020\, Los Angeles\, USA | International Confer ence On Neurorehabilitation and Its Associated Disorders\, June 06 -07\, S ingapore | Global Insight Conference on Neurology &\; Brain Disorders\, October 18 - 20\, 2020\, Las Vegas\, USA | Dementia 2020 conference\, Apr il 16-18\, 2020 Tokyo\, Japan | International Conference on Neurology and Brain disorders June 04-06\, 2020\, Rome\, Italy | Annual Conference on De mentia and Alzheimers Disease\, December 13-15\, 2020\, Abu Dhabi\, UAE | World Congress on Neurology and Neurodisorders\, July 16-17\, 2020\, Melbo urne\, Australia |
\n\nRelated societies: American Parkinson Disease Association: Hope in Progress | Dementia Alliance Intern ational | Dementia Advocacy and Support Network International | Internatio nal Psychogeriatric Association | World Federation of Neurology | Child Ne urology Society | American Neurological Association |
\nScope and Importance
\n\nDementia is out broken as the majo r threat in the UK. It is stated that\, by now there are around 800\,000 p eople in UK with dementia and the numbers are expected to rise to 1\,142\, 677 by 2025 and 2\,092\,945 by 2051.
\n\n\n\n \;
\n\nIt is also reported that around 45 000 p eople below the age of 65 are suffering from early onset of dementia and 7 73\,502 are in late onset of Dementia. 311\,730 (39%) of people living wit h dementia over 65 are living in care homes (either residential care or nu rsing homes) and 493\,639 (61%) are living in the community among the peop le.Based on the onset of disease\, more people are prone to Dementia in th e late onset period. During the late onset period i.e.\, between the age o f 65 to 95* women develop the disease more frequently than men. There are more women patients and victims than men in the late onset case. During th e early onset of the disease i.e.\, between the age group 30-64 men are mo re prone to the disease than women.
\n\n \;
\n\n\n\nAmong the Dementia sub types\, Alzheimer &rsquo\;s is the major type contributing to 62% among all the sub types\, and amidst the other sub types next ranks the Vascular Dementia which cont ributes for about 17% of the cases. Next lies the mixed dementia which is ranking third in prevalence. The other sub types which include Dementia wi th Lewy bodies is found in 4% of people\, Frontotemporal dementia in 2%\, Parkinson&rsquo\;s dementia in 2%. The other associated diseases with deme ntia contributes around 3 % of the cases.
\n\n\n\nDementia with not only ruining the life of people al so cause a major impact on the economy in the society. The greater part of the cost spent on Dementia care fall under three main categories health c are cost\, social care cost\, informal care costs. The health care which i ncludes hospitalization and treatment contributes about 16.4% of total cos t\, the social care which involves the care given by the nursing homes\, h ome care contributes about 39 % of cost and the rest 44.6% comes under the informal care which the given by the family or friends related to the pat ient.
\n\n\n\nList o f Universities carrying out research in Dementia in UK\,
\n\n< ul>\nBoth the Gover nment and the Charities help the universities and the Collaborative Resear ch centres to carry out Dementia research in developing novel medicines fo r dementia. The list of Governmental funding agents\, Non-Governmental Org anizations and Companies providing funds for Dementia Research in UK inclu des the following\,
\n\nDrugs that a re available in the market for the treatment of dementia includes Memantin e\, Donepezil\, Rivastigmine\, Galantamine. Among these drugs Donepezil is considered as the most effective one\, since it has cured dementia in abo ut 59\,931 people. It is also reported that about 30\,000 people are treat ed with Rivastigmine. The Memantine ranks third in treating about 14\,640 patients\, the Galantamine drug cures Dementia in about 10\,000 patients.< /p>\n
Conference Date September 24-25\, 2020 p>\n
For Sponsors &\; Exhibitors Sponsorshi p Opportunities
\nSpeaker Opportunity
\n